Logan Coy Related postsA First-in-Human, Multicenter, Phase 1, Open-Label Study of XTX301 in Advanced Solid TumorsSeptember 11, 2026Efficacy & Safety of Olvimulogene Nanivacirepvec & Platinum-doublet + Physician’s Choice of Immune Checkpoint Inhibitor Compared to Docetaxel in NSCLC (VIRO-25)September 11, 2026A Phase 2, Randomized, Open-label Study of Momelotinib in Participants with Anemia due to Low-risk Myelodysplastic SyndromeSeptember 11, 2026 Previous postA Phase 1, Open-Label, Multicenter, Dose Escalation Study of SGR-1505 as Monotherapy in Mature B-Cell MalignanciesNext postA Phase 1 Study of IM-1021 in Participants with Advanced Malignancies